Paul discusses the complexities of scaling biotechnology, emphasizing the significant capital investment and lengthy research cycles involved. He highlights the shift in investor sentiment from long-term, patient capital to a demand for quicker profitability, reflecting broader market changes. Steve's perspective on the need for sustainable alternatives to traditional food production underscores the urgency of innovation in this sector.
